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Introduction 
FK-506 (TacrolimusjPrograf 1M) is a new immunosuppressive agent recently 
approved by the Food and Drug Administration. Although it is formally indicated for 
use only in patients undergoing orthotopic liver transplantation,l-4 it has been used 
clinically after transplantation of essentially all solid and hollow organs,5-7 and both 
bone marrow8,9 and pancreatic islets. 10 It has been used for over 5 years in renal 
transplant patients, both as the primary immunosuppressive agent,11-16 and in an 
attempt to rescue failing kidneys.17 This chapter will summarize our clinical experience 
with adult and pediatric renal transplant patients, both in the primary and rescue 
setting, and will touch also on our series of bone marrow augmentation.18 We hope 
to demonstrate that FK-506 is an excellent immunosuppressive agent for patients 
undergoing renal transplantation and that it represents formidable addition to our 
armamentarium. 
Early Experience 
The first 2 years' experience with FK-506 in renal transplant patients included 
a pilot series, a small randomized trial comparing FK-506 with Cyclosporine, and a 
larger group of patients not eligible for the randomized trial who were given the choice 
1 
of receiving FK-506. The latter group included a disproportionately high percentage 
of patients undergoing retransplantation who had failed conventional therapy in the 
past, often at other centers. These 240 cases were compared with a roughly 
concurrent group of 196 cases managed with conventional Cyclosporine-based 
immunosuppression. 19 The patients in the randomized trial were also analyzed 
separately, with similar outcomes to the larger group. Comparable patient and graft 
survival were seen between FK-506 and Cyclosporine treated patients. (Table 1) 
However, over 40% of the patients on FK-506 were able to be taken off prednisone, 
and antihypertensive medication requirements were lower in the FK-506 group. In 
addition, serum cholesterol levels were significantly lower in the FK-506 treated 
patients. The conclusion of this early work, a time when the dosing and toxicities were 
still being evaluated, was that FK-506 was certainly as effective as conventional 
therapy and might have some advantages with regard to secondary issues. 
The Second Randomized Trial - FK506/Prednisone vs. FK506/Azathioprine/ 
Prednisone 
On the basis of these results, a prospective, randomized open label trial was 
begun in August, 1991, comparing two FK506-based regimens, with and without 
Azathioprine (Table 2).12,13,20,21 This trial was limited to adults undergoing kidney 
transplantation alone who consented to enter the trial. Children, patients receiving 
multiple concomitant organs, and patients who refused, were excluded. The patient 
population was otherwise unselected, with 25% of the patients undergoing 
retransplantation, 13% having a panel reactive antibody of over 40%, and 18% of the 
patients being over the age of 60. Date on all 397 cases entered into the trial, which 
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ended December 9, 1993, were recently presented. 13 The overall 1 and 2 year 
actuarial patient survival was 95% and 93%, and the overall 1 and 2 year actuarial graft 
survival was 89% and 83%. (Table 3, Figure 1). No significant differences in patient 
or graft survival were seen between the double and triple drug regimens. 
A multivariate analysis was performed to search for any factors predictive of 
graft survival. The only factor found was the presence or absence of early graft 
function. The 1 and 2 year actuarial graft survival for patients with immediate graft 
function was 94% and 89%; however, in patients with initial non-function (defined either 
as lack of urine output within the first 48 hours or the need for dialysis within the first 
week after transplantation), the 1 and 2 year actuarial graft survival was 78% and 71% 
(Figure 2 - P < .0001, relative risk 3.53, range 2.09-5.91). Other factors, such as the 
presence or absence of rejection, recipient age or race, antibody level, or 
primary/retransplant status, were not associated with differential outcomes (see Table 
4). 
The mean serum creatinine was 2.0 ± 1.1 mg/dl, and the calculated creatinine 
clearance was 56 ± 27 ml/min. The mean BUN was 32 ± 16 mg/dl. There was no 
difference between the two groups. 
Triple therapy was associated with less rejection than double therapy, both in 
patients treated with steroids (44% versus 54%, P < .05), and in those requiring 
antilymphocyte therapy (7% versus 14%, P<.04). The incidence of other adverse 
events, such as early non-function, CMV, PTLD, and new onset diabetes, was not 
influenced by immunosuppressive group (Table 5). 
Forty-nine percent of the successfully transplanted patients were weaned off 
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steroids. Thirty-five percent of the patients were off antihypertensive medications, and 
39% were on 1 medication only. The mean serum cholesterol was 195 ± 49 mg./dl. 
There were no differences between the two groups in these parameters (Table 6). 
There was a high incidence of cross-over, more from triple to double therapy 
(40%) than from double to triple therapy (17%). 
This study concluded that FK-506 was an effective immunosuppressive agent 
in renal transplant patients, with excellent 1 and 2 year patient and graft survival, and 
an ability to wean steroids in nearly half and antihypertensive medications in over one-
third of the patients. The benefit of Azathioprine was limited to a reduced incidence 
of rejection, but no benefit was seen in terms of patient or graft survival. Given the 
need to discontinue Azathioprine in 40% of the patients initially randomized to triple 
therapy, it was felt that Azathioprine as a third agent was of somewhat limited 
usefulness, and that perhaps one of the new Azathioprine substitutes, such as 
Mycophenolate Mofetil,22 or Brequinar,23 might be worth evaluating. In the interim, a 
new randomized trial of FK-506-based therapy was started, comparing FK-
506/Prednisone with FK-506/Prednisone and a one week course of low-dose 
Cyclophosphamide. This trial is ongoing. 
Pediatric Transplantation 
Pediatric renal transplantation accounts for about 7% of the caseload in our 
institution. Given both the small number of cases and the nature of the patient 
population, a randomized trial was not possible in our pediatric patients. In addition, 
results with cyclosporine-based therapy in the pediatric patients were quite reasonable, 
with 100% and 97% one and four year actuarial patient survival and 100% and 85% 
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one and four year actuarial graft survival. 14,24 However, the ability to withdraw steroids 
seemed particularly important in children, and, by January, 1994, 43 cases had been 
performed under FK-506 therapy.25 Thirty-five percent of these cases were 
retransplantations, many in children previously transplanted elsewhere. Twelve 
percent were in sensitized children. About half were with kidneys from living donors. 
Results demonstrated 100% patient survival at one and three years (Table 7, 
Figure 3). The one and three year actuarial graft survival was 98% and 85%. The 
mean serum creatinine was 1.2 ± 0.6 mg/dl, and the calculated creatinine clearance 
was 75 ± 23 ml/min/1.73 m2. The mean BUN was 26 ± 11 mg/dl. 
Sixty-two percent of the children were weaned off steroids, and the associated 
effect on growth is shown in Table 8. Preadolescent children off steroids had the most 
dramatic changes and actually went beyond catch-up growth to become slightly taller 
than average. 
The main adverse events are listed in Table 9. The most important 
complications were viral infections. CMV was seen in 6 (14%) children, 5 of whom 
were seronegative recipients of organs from seropositive donors. Intravenous 
gancyclovir was used successfully in all cases. EBV-associated PTLD was also seen 
in 5 (12%) cases; immunosuppression was temporarily withdrawn, and antiviral therapy 
with Gancyclovir or Acyclovir was initiated. In all cases, the PTLD resolved with good 
preservation of graft function. These complications probably represent a learning 
curve in the use of FK-506 in children, as no new cases of PTLD have been seen in 
patients transplanted during the past 21 months (as of October, 1994). 
Rejection was seen in 58% of patients; 7% required antilymphocyte therapy. 
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All rejections were biopsy proven, and most occurred within the first two weeks after 
transplantation. 
The pediatric data demonstrated that excellent results can be obtained with FK-
506. In addition, the ability to wean steroids in a majority of children has led to 
significant improvements in growth. 
Rescue ({L, 0 
The first use of FK-506 in a renal transplant patient was in an attempt to rescue -; 
'I'( ,-r, ~ "'I 4A- aKId~"Dtff"IKcKE II 411f~i , ... ~ ~D~Did/~ 
a chronically rejecting allOgratthhis attempt failed (the patient went on to receive a . 
second kidney under FK506 immunosuppression, and it is functioning well 5 years 
later), as did the next 5 attempts at rescue. Most of these early efforts were in 
retrospect, poorly indicated, as the patients had a significant degree of scarring and/or 
chronic rejection. However, when rescue was attempted in patients with acute 
rejection who had failed conventional therapy, a number of allografts were salvaged. 
In both adults and children, 70-74% of patients were successfully rescued. 17,25,26 In 
patients with acute cellular rejection only, the success rate was 85%; in patients with 
both cellular and vascular rejection, the success rate was 65%, and in patients with 
acute cellular rejection and primary non-function of the allograft, the success rate was 
only 40% (Table 10). Seventy-nine percent of the patients had received one or more 
courses of antilymphocyte therapy prior to being referred for rescue. Eighty-three 
percent had been transplanted elsewhere. Twenty-three percent of the patients 
arrived on dialysis; half of them were successfully rescued. Twenty-one percent of 
successfully rescued patients were able to be weaned off Prednisone. Thus, FK-506 
has been useful in salvaging the majority of the patients with refractory acute rejection 
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under conventional therapy. 
Bone Marrow Augmentation 
While this subsection has perhaps less to do specifically with FK-506, it 
discusses an area of increasing importance in our clinical program. This project 
began with the observation that patients with extremely long graft survival (27-29 
years) were found to be micro-chimeric with respect to the donor.27-30 Donor cells 
were found not only in the allograft but also in the peripheral blood, skin, and lymph 
nodes. On the basis of this observation, we postulated that infusion of donor bone 
marrow at the time of the transplant would augment chimerism in the recipient. 18 The 
first combined, simultaneous kidney/bone marrow transplantation was performed on 
December 14, 1992. An early report of the first 10 patients was presented in May, 
1994, at the American Society of Transplant Surgeons.18 By September 27,1994,30 
kidney/bone marrow transplantations had been performed. In 6 cases, pancreatic 
islets were also infused, and in 4 cases, a pancreas transplant was also performed. 
Immunosuppression was with routine FK-506 and steroids; the pancreas recipients 
also received Azathioprine, 2 mg/kg/d. All patients, except one, were undergoing 
their first transplant. Radiation therapy, cytoreduction therapy, or induction 
antilymphocyte therapy was not given. Nineteen concurrent control patients, who did 
not receive bone marrow (usually because of refusal of the donor family to consent 
to vertebral body recovery), were also studied. Immunologic testing for chimerism 
was performed prior to transplantation and at regular intervals post-transplantation. 
With a mean follow-up of 8.0 ± 6.4 months, all study patients are alive, and 28 
(93%) have functioning renal allografts (Table 11). Two kidney/bone marrow patients 
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have lost their allografts at 16 months after transplantation, one to non-compliance and 
one to rejection. The mean serum creatinine is 1.8 ± 0.6 mgjdl, and the BUN is 30 
± 9 mgjdl. In the control patients, 18 (95%) patients are alive and 17 (89%) have 
functioning kidneys, with a mean serum creatinine of 2.3 ± 1.3 mgjdl and a BUN of 
35 ± 14 mgjdl. The incidence of early non-function, rejection, and CMV was 
comparable between study and control patients and is shown in Table 11. Graft vs. 
host disease was not seen in any study or control patient. 
The chimerism studies in the May, 1994, presentation suggested routine 
augmentation in all of the nine evaluable patients, as documented either by flow 
cytometry, PCR, or fluorescent in-situ hybridization (for V-chromosome analysis). 
Chimerism was also seen in the control patients, but less often (3 or 5 evaluable 
patients) and to a lesser degree. Unpublished data on the larger group seems to be 
similar, although the analysis is still in progress. 
The conclusions drawn thus far from the experience are that kidney jbone 
marrow transplantation is straightforward and safe to perform, that it is associated with 
routine augmentation of chimerism, that graft vs. host disease is not a problem, that 
excellent patient and graft survival are obtained, and that the early events after 
transplantation are not affected. More follow-up will be required to access the long-
term outcome with bone marrow augmentation. 
Toxicity 
FK-506 has the same toxicities that have been seen with cyclosporine, namely 
nephrotoxiCity, neurotoxicity, and diabetogenicity.31-37 In general, these side effects are 
similar in degree and reversibility. The initial incidence of new onset diabetes has 
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been as high as 18%_20%;13,37 however, much of this is reversible with reduction in 
both the FK-506 and the steroid dosage, and the final incidence of new onset insulin 
dependence, 6-10%, is about the same as that reported with cyclosporine.38-40 
CONCLUSIONS 
It is fair to say that FK-506 has dramatically changed the outcome of renal 
transplantation in our institution. As a program committed to transplanting relatively 
high-risk patients, we have previously reported 1 year actuarial graft survivals of 74-
80%.41-42 Our most recent data in adults have shown a 15% improvement in 1 and 2 
year actuarial graft survival, as well as an ability to discontinue steroids in half of the 
patients. In pediatric patients, the use of FK-506 has enabled us to achieve the same 
good primary outcomes and for the first time allowed dramatic gains in height in the 
majority of patients weaned off prednisone. The ability to salvage over 70% of renal 
allografts failing conventional immunosuppression has also proved to be an important 
advantage. Finally, the development of bone marrow augmentation protocols has 
allowed the exploration of chimerism in renal transplant patients, and this may have 
important long-term implications. What FK-506 has not eliminated are the problems 
of acute rejection and the persistence of antibody-mediated events. In addition, the 
same fundamental toxicities seen with cyclosporine are present with FK-506; 
unfortunately, a T-cell active immunosuppressive agent without these side effects does 
not yet exist. For now, notwithstanding the problems noted above, it can be said that 
FK-506, in our hands, represents a significant step forward in immunosuppression for 
kidney transplant patients. 
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SUMMARY 
1. In an unselected adult renal transplant population, FK-506 as the primary 
immunosuppressive agent has been associated with a one and two year 
actuarial patient survival of 95% and 93% and 1 and 2 year actuarial graft 
survival of 89% and 83%. Forty-nine percent of successfully transplanted 
patients have been weaned off steroids. 
2. In pediatric renal transplant patients, FK-506 has been associated with 100% 
one and three year actuarial patient survival and 98% and 85% one and three 
year actuarial graft survival. 62% of successfully transplanted patients have 
been taken off prednisone, with dramatic improvements in height. 
3. FK-506 has been successful in rescuing 70-74% of adult or pediatric renal 
transplant patients with acute rejection that has failed conventional therapy. 
4. Kidney /bone marrow transplantation under FK-506 therapy has been 
successfully performed, without graft vs. host disease and with routine 
augmentation of chimerism. 
5. The side effects of FK-50S include nephrotoxicity, neurotoxicity, and 
diabetogenicity; they are comparable to those seen with cyclosporine. 
S. FK-506 is an important new addition to the immunosuppressive armamentarium 
in renal transplant patients. 
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FIGURE LEGENDS 
Figure 1: Actuarial Patient and Graft Survival 
Figure 2: Graft Survival in Patients With and Without Initial Graft Function 
Figure 3: Pediatric Kidney Transplantation Under FK506 - Patient and Graft Survival 
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TABLE 1 
EARLY EXPERIENCE WITH FK506 IN RENAL TRANSPLANTATION 
IMMUNOSUPPRESSION FK506 CYCLOSPORINE 
N 240 196 
1 Yr. Actuarial Patient Survival 90% 94% 
1 Yr. Actuarial Graft Survival 74% 77% 
Off Steroids 44% 0% 
Off Anti-hypertensive Medications 43% 25% 
Cholesterol (mg/dl) 187 ± 51 236 ± 59* 
* p<.0001 
Preop 
TABLE 2 
IMMUNOSUPPRESSIVE PROTOCOL -
FK506/PREDNISONE VS. FK506/ AZATHIOPRINE/PREDNISONE 
IMMUNOSUPPRESSION 
FK506 STEROIDS AZATHIOPRINE 
0.15 mg/kg po Methylprednisolone IV 3 mg/kg 
1000 mg 
Postop 0.1 mg/kg IV Methylprednisolone IV 3 mg/kg/d 
Continuous Infusion 50 mg IV q 6h x 4 doses 
40 mg IV q 6h x 4 doses 
30 mg IV q 6h x 4 doses 
0.15 mg/kg po bid 20 mg IV 6h x 4 doses 
when taking po 20 mg IV q 12h x 2 
Prednisone 20 mg po qd 
TABLE 3 
FK506/PREDNISONE VS. FK506/AZATHIOPRINE/PREDNISONE -
ACTUARIAL SURVIVAL 
FK506/Pred FK506/ Aza/Pred Overall 
N 199 198 397 
Patient 
1 Yr. 97% 94% 95% 
2 Yrs. 95% 90% 93% 
Graft 
1 Yr. 90% 88% 89% 
2 Yrs. 86% 79% 83% 
p=ns 
TABLE 4 
FK506/PREDNISONE VS. FK506/ AZATHIOPRINE/PREDNISONE 
SELECTED SUBGROUP ANALYSIS - ACTUARIAL GRAFT SURVIVAL 
(OVERALL RESULTS) 
1 Year 2 Years 
First Cadaver 91% 82% 
Retransplant 83% 80% 
PRA> 40% 87% 85% 
Recipient Age ~ 60 yrs. 87% 75% 
Black Recipient 88% 74% 
No Rejection 91% 86% 
Rejection 87% 79% 
*No ATN 94% 89% 
ATN 78% 71% 
* p< .0001 
TABLE 5 
FK506/PREDNISONE VS. FK506/AZATHIOPRINE/PREDNISONE 
ADVERSE EVENTS 
FK506/PRED FK506/ AZA/PRED OVERALL 
Rejection-Steroids 54% 44% 49%* *p<.05 
Rejection- 14% 7% 10%+ +p<0.04 
OKT3/ATG 
ATN 36% 33% 35% 
CMV 15% 16% 16% 
PTLD 2% 1% 1% 
New Onset 12% 9% 10% 
Diabetes 
TABLE 6 
FKS06/PREDNISONE VS. FKS06/ AZATHIOPRINE/PREDNISONE 
FKS06/PRED FKS06/ AZA/PRED OVERALL 
Off Steroids 50% 49% 49% 
Off Anti- 37% 34% 35% 
hypertensive 
medications 
Serum 192 ± 52 199 ± 45 195 ± 49 
Cholesterol 
(mg/dl) 
N=43 
Patient 
Graft 
TABLE 7 
PEDIATRIC KIDNEY TRANSPLANTATION UNDER FK506 
ACTUARIAL SURVIVAL 
One Year Three Years 
100% 100% 
98% 85% 
--------~K-K--------K---
TABLE 8 
GROWTH AFTER PEDIATRIC KIDNEY TRANSPLANTATION UNDER FK506 
Z-SCORE (± SO) 
ON STEROIDS OFF STEROIDS 
~ 12 Years > 12 Years ~ 12 Years > 12 Years 
Time 
At Transplant -1.9 (± 1.2) -3.0 (± 1.1) -2.7 (± 1.3) -2.3 (± 2.6) 
3 Months -1.7 (± 0.9) -2.9 (± 1.0) -1.5 (± 0.7) -2.6 (± 2.3) 
6 Months -1.2 (± 1.2) -2.7 (± 1.1) -0.8 (± 0.8) -2.1 (± 2.5) 
1 Year -0.4 (± 1.1) -2.1 (± 1.1) -0.02 (± 1.7) -1.6 (± 2.4) 
Most Recent -0.42 (± 1.7) -2.0 (± 1.1) +0.92 (± 1.64) -1.4 (± 2.3) 
TABLE 9 
PEDIATRIC KIDNEY TRANSPLANTATION UNDER FK506 
ADVERSE EVENTS 
Rejection - Steroids 58% 
OKT3/ATG 7% 
CMV 14% 
PTLD 12% 
ATN 7% 
Temporary New Onset Diabetes 7% 
(Resolved in all cases) 
-K~----- ._----
TABLE 10 
FK506 RESCUE THERAPY IN RENAL TRANSPLANTATION 
N 77 
Successful Rescue 
Overall 74% 
Acute Cellular Rejection 85% 
Cellular + Vascular Rejection 65% 
Cellular Rejection and 10 Non-function 40% 
On Dialysis 50% 
Off Steroids 21% 
TABLE 11 
KIDNEY IBONE MARROW CONTROL 
N 30* 19 
Patient Survival 100% 95% 
Graft Survival 93% 89% 
Graft vs. Host Disease 0% 0% 
Rejection 73%+ 58% 
OKT3 13% 11% 
ATN 17% 16% 
CMV 13% 16% 
Off Steroids 21% 22% 
* Includes 6 kidney/islet/bone marrow 
4 kidney Ipancreas/bone marrow 
+ p=0.26 
